Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2024; 30(26): 3261-3263
Published online Jul 14, 2024. doi: 10.3748/wjg.v30.i26.3261
Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients
Li-Yang Meng, Chao-Ting Yang, Jian-Feng Bao, Jin-Song Huang
Li-Yang Meng, Chao-Ting Yang, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Jian-Feng Bao, Jin-Song Huang, Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou 310023, Zhejiang Province, China
Author contributions: Meng LY and Yang CT wrote the manuscript with the support from Huang JS; Bao JF edited this letter; Huang JS conceived the original idea.
Supported by Biomedical Enterprise Project of Hangzhou Science and Technology Bureau, No. 2021WJCY061 and No. 2022WJC230.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin-Song Huang, Doctor, Chief Doctor, Department of Hepatology, Hangzhou Xixi Hospital, Zhejiang University School of Medicine, No. 2 Hengbu Road, Hangzhou 310023, Zhejiang Province, China. huangjinsongyz@126.com
Received: April 28, 2024
Revised: May 30, 2024
Accepted: June 21, 2024
Published online: July 14, 2024
Processing time: 72 Days and 8 Hours
Core Tip

Core Tip: It is well known that every chronic hepatitis B (CHB) patient should receive antiviral therapy. Although nucleos(t)ide analogs are still the first choice for CHB treatment, they are associated with many side effects, such as renal damage, osteoporosis, and lipid metabolism disorders. Therefore, as a new antiviral drug in China, tenofovir amibufenamide (TMF) is as effective as tenofovir alafenamide (TAF) in treating CHB and has comparable safety profiles, which suggests that TMF may be a viable alternative to TAF for CHB treatment.